Towards responsible ctDNA-based multi-cancer screening: a preliminary exploration and discussion of ethically relevant aspects
2022

Ethical Aspects of ctDNA-based Multi-Cancer Screening

Sample size: 140000 publication Evidence: moderate

Author Information

Author(s): Wybo Dondorp, Guido de Wert

Primary Institution: Maastricht University

Hypothesis

What are the ethical implications of using ctDNA for multi-cancer screening?

Conclusion

The study highlights the need to consider ethical challenges in the development of ctDNA-based multi-cancer screening.

Supporting Evidence

  • MCED tests need validation in large-scale studies.
  • Ethical challenges include the potential for harm and overdiagnosis.
  • Screening should have defined objectives and minimize risks.

Takeaway

This study talks about using a blood test to find many types of cancer early, but we need to think about the ethical issues that come with it.

Methodology

The paper explores ethical aspects of ctDNA-based multi-cancer screening through a review of existing literature and ethical frameworks.

Potential Biases

Potential for false reassurance and overdiagnosis due to low sensitivity of current tests.

Limitations

The study does not provide empirical data from large-scale validation studies yet.

Participant Demographics

Non-patient populations aged 50 to 79 for the GALLERI test pilot.

Digital Object Identifier (DOI)

10.20517/evcna.2022.23

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication